MIDDLE EAST & AFRICA DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Middle East & Africa Diabetes Drugs Market is segmented by Product Type (Oral Anti-diabetic Drugs, Insulin, Non-Insulin Injectable Drugs, and Combination Drugs) and Geography.

Market Snapshot

 Middle East & Africa Diabetes Drugs Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: 0 %
 Middle East & Africa Diabetes Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • The Middle East & Africa diabetes drugs market (henceforth, referred to as the market studied) was valued at USD 2793.99 million in 2018, and it is expected to witness a CAGR of 6.48% during the forecast period 2019 - 2024, primarily due to the growing geriatric population.
  • In most countries in the Middle East region, it is estimated that approximately USD 17 billion are spent on diabetes by consumers.
  • The major cause for the growing diabetic population in this region is unhealthy lifestyles and urbanization.
  • Most of the countries in the region has seen tremendous economic and industrial development in recent times, resulting in a shift in social behaviors.

Scope of the Report

The Middle East & Africa diabetes drugs market is segmented by product type (oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs) and geography.

By Product Type
Oral Anti-diabetic Drugs
Biguanide (Value and Volume 2012-2024)
Metformin
Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha - Glucosidase Inhibitors
Sodium - glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2024)
Sulfonylureas
Meglitinide (Value and Volume 2012-2024)
Meglitinide
Insulin
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-Insulin Injectable Drugs
GLP1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Combination Drugs
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
Middle East & Africa (Value and Volume, 2012-2024)
Saudi Arabia
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
Iran
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
Egypt
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
Oman
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
South Africa
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies
Rest of Middle & Africa
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

Report scope can be customized per your requirements. Click here.

Key Market Trends

Around 16 million People are Suffering from Diabetes in the Middle East & Africa Region

  • In Middle East & Africa (MEA), 15.51 million people are suffering from diabetes, and this population is expected to increase in the forecast period with a CAGR of 4.46%.
  • In the MEA region, in 2018, the obesity rate was high with 42 million people, which was 21% of the total population. Obesity may lead to type-2 diabetes in the future.
  • Egypt and Saudi Arabia have the highest diabetic population, with 53.3% and 28.2% market share in the market studied, respectively.
  • For most of the population, sedentary lifestyles and endless fast-food options have replaced the traditional ways of work, travel, and cuisine, increasing the chance of getting diseases, such as type-2 diabetes.
  • Increasing population and rising per capita income in these countries may result in increasing healthcare expenditure, which may drive the market studied during the forecast period (2019-2024).
 Middle East & Africa Diabetes Drugs Market Key Trends

Saudi Arabia Holds the Highest Market Share

  • Saudi Arabia accounts for the largest market share in the MEA diabetic drugs market, which is close to 25.35% in 2018, and Oman is expected to witness the highest growth rate of 10.45% during the forecast period (2019-2024).
  • The increasing sales of diabetic drugs in Saudi Arabia are due to the growing prevalence of diabetes in the country.
  • The Middle Eastern countries have high diabetes prevalence, like Saudi Arabia - 24%, Kuwait - 23%, Bahrain - 22%, Qatar - 20%, and UAE - 19%.
  • In 2018, insulin accounted for close to 33.37% of market share in the market studied. The insulin segment of the market studied in the MENA region was valued at 932.27 million in 2018, and it is expected to register a CAGR of 4.12% during the forecast period (2019-2024), where Saudi Arabia is expected to occupy 32.33% of the market share.
 Middle East & Africa Diabetes Drugs Market Growth by Region

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market studied.

  • Glynase and Diatab, which are considered to be generic medication, had high sales in the Middle East region, but were deemed to fall below the standards of the treatment, on which they were based. Thus, with the notification of the Saudi Food and Drug Authority (SFDA), the decision of withdrawing these drugs was announced by the National Health Regulatory Authority (NHRA). 
  • A new study on SGLT2 Class (Jardiance, Farxiga) reflects that the drug helps in treating kidney and cardio vascular diseases.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Oral Anti-diabetic Drugs

        1. 5.1.1.1 Biguanide (Value and Volume 2012-2024)

          1. 5.1.1.1.1 Metformin

        2. 5.1.1.2 Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)

          1. 5.1.1.2.1 Alpha - Glucosidase Inhibitors

        3. 5.1.1.3 Sodium - glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)

          1. 5.1.1.3.1 Invokana (Canagliflozin)

          2. 5.1.1.3.2 Jardiance (Empagliflozin)

          3. 5.1.1.3.3 Farxiga/Forxiga (Dapagliflozin)

          4. 5.1.1.3.4 Suglat (Ipragliflozin)

        4. 5.1.1.4 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

          1. 5.1.1.4.1 Januvia (Sitagliptin)

          2. 5.1.1.4.2 Onglyza (Saxagliptin)

          3. 5.1.1.4.3 Tradjenta (Linagliptin)

          4. 5.1.1.4.4 Vipidia/Nesina (Alogliptin)

          5. 5.1.1.4.5 Galvus (Vildagliptin)

        5. 5.1.1.5 Sulfonylureas (Value and Volume 2012-2024)

          1. 5.1.1.5.1 Sulfonylureas

        6. 5.1.1.6 Meglitinide (Value and Volume 2012-2024)

          1. 5.1.1.6.1 Meglitinide

      2. 5.1.2 Insulin

        1. 5.1.2.1 Basal or Long Acting Insulins

          1. 5.1.2.1.1 Lantus (Insulin Glargine)

          2. 5.1.2.1.2 Levemir (Insulin Detemir)

          3. 5.1.2.1.3 Toujeo (Insulin Glargine)

          4. 5.1.2.1.4 Tresiba (Insulin Degludec)

          5. 5.1.2.1.5 Basaglar (Insulin Glargine)

        2. 5.1.2.2 Bolus or Fast Acting Insulins

          1. 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.2.2.2 Humalog (Insulin Lispro)

          3. 5.1.2.2.3 Apidra (Insulin Glulisine)

        3. 5.1.2.3 Traditional Human Insulins

          1. 5.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.2.3.2 Humilin

          3. 5.1.2.3.3 Insuman

        4. 5.1.2.4 Biosimilar Insulins

          1. 5.1.2.4.1 Insulin Glargine Biosimilars

          2. 5.1.2.4.2 Human Insulin Biosimilars

      3. 5.1.3 Non-Insulin Injectable Drugs

        1. 5.1.3.1 GLP1 Receptor Agonists

          1. 5.1.3.1.1 Victoza (Liraglutide)

          2. 5.1.3.1.2 Byetta (Exenatide)

          3. 5.1.3.1.3 Bydureon (Exenatide)

          4. 5.1.3.1.4 Trulicity (Dulaglutide)

          5. 5.1.3.1.5 Lyxumia (Lixisenatide)

      4. 5.1.4 Combination Drugs

        1. 5.1.4.1 Insulin Combinations

          1. 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

          2. 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

          3. 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

        2. 5.1.4.2 Oral Combination

          1. 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

    2. 5.2 Geography

      1. 5.2.1 Middle East & Africa (Value and Volume, 2012-2024)

        1. 5.2.1.1 Saudi Arabia

          1. 5.2.1.1.1 Oral Anti-diabetic Drugs

          2. 5.2.1.1.2 Insulin

          3. 5.2.1.1.3 Non-Insulin Injectable Drugs

          4. 5.2.1.1.4 Combination Drugs

          5. 5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        2. 5.2.1.2 Iran

          1. 5.2.1.2.1 Oral Anti-diabetic Drugs

          2. 5.2.1.2.2 Insulin

          3. 5.2.1.2.3 Non-Insulin Injectable Drugs

          4. 5.2.1.2.4 Combination Drugs

          5. 5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        3. 5.2.1.3 Egypt

          1. 5.2.1.3.1 Oral Anti-diabetic Drugs

          2. 5.2.1.3.2 Insulin

          3. 5.2.1.3.3 Non-Insulin Injectable Drugs

          4. 5.2.1.3.4 Combination Drugs

          5. 5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        4. 5.2.1.4 Oman

          1. 5.2.1.4.1 Oral Anti-diabetic Drugs

          2. 5.2.1.4.2 Insulin

          3. 5.2.1.4.3 Non-Insulin Injectable Drugs

          4. 5.2.1.4.4 Combination Drugs

          5. 5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        5. 5.2.1.5 South Africa

          1. 5.2.1.5.1 Oral Anti-diabetic Drugs

          2. 5.2.1.5.2 Insulin

          3. 5.2.1.5.3 Non-Insulin Injectable Drugs

          4. 5.2.1.5.4 Combination Drugs

          5. 5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

        6. 5.2.1.6 Rest of Middle & Africa

          1. 5.2.1.6.1 Oral Anti-diabetic Drugs

          2. 5.2.1.6.2 Insulin

          3. 5.2.1.6.3 Non-Insulin Injectable Drugs

          4. 5.2.1.6.4 Combination Drugs

          5. 5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Other Companies

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetic Population (2012-2024)

    2. 6.2 Type-2 Diabetic Population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Takeda

      2. 7.1.2 Pfizer

      3. 7.1.3 Eli Lilly

      4. 7.1.4 Janssen Pharmaceuticals

      5. 7.1.5 Astellas

      6. 7.1.6 Boehringer Ingelheim

      7. 7.1.7 Merck And Co.

      8. 7.1.8 AstraZeneca

      9. 7.1.9 Bristol Myers Squibb

      10. 7.1.10 Novartis

      11. 7.1.11 Sanofi

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The MEA Diabetes Drugs Market market is studied from 2016 - 2027.

The MEA Diabetes Drugs Market is growing at a CAGR of 0% over the next 5 years.

Boehringer Ingelheim, Astrazeneca, Eli Lilly, Sanofi, Novo Nordisk are the major companies operating in MEA Diabetes Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!